Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2025 | Results of ARES: allogeneic microbiotherapy for ruxolitinib-refractory GvHD with GI involvement

Florent Malard • 7 Dec 2025
ASH 2025
General MaaT013 Ruxolitinib
ARES

Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, discusses the Phase III ARES trial (NCT04769895) of MaaT013, an allogeneic microbiotherapy, for ruxolitinib-refractory acute graft-versus-host disease (GvHD) with gastrointestinal (GI) involvement. Dr Malard reports encouraging response rates. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Florent Malard

Results of a survey investigating fertility and outcomes after CAR T-cell therapy 1:13
Results of a survey investigating fertility and outcomes after CAR T-cell therapy
Florent Malard • 7 Dec 2025
The potential impact of antibiotic exposure before CAR-T on therapeutic outcomes 1:17
The potential impact of antibiotic exposure before CAR-T on therapeutic outcomes
Florent Malard • 31 Mar 2025
The potential of microbiome modulation for preventing and treating acute GvHD 1:04
The potential of microbiome modulation for preventing and treating acute GvHD
Florent Malard • 31 Mar 2025
Refining the use of PTCy for GvHD prophylaxis 1:10
Refining the use of PTCy for GvHD prophylaxis
Florent Malard • 31 Mar 2025

Related Videos

Results of a survey investigating fertility and outcomes after CAR T-cell therapy 1:13
Results of a survey investigating fertility and outcomes after CAR T-cell therapy
Florent Malard • 7 Dec 2025
Key barriers to equitable hematologic care in India and priorities for the next decade 6:21
Key barriers to equitable hematologic care in India and priorities for the next decade
Rohan Halder • 25 Nov 2025
Strategies to enhance patient education and support for transplant and CAR-T therapies 2:51
Strategies to enhance patient education and support for transplant and CAR-T therapies
Rohan Halder • 25 Nov 2025
Opportunities and challenges for real-time AI decision support in transplant care 4:47
Opportunities and challenges for real-time AI decision support in transplant care
Amin Turki • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals